EMEA-000527-PIP05-17

Key facts

Invented name
Lucentis
Active substance
ranibizumab
Therapeutic area
Ophthalmology
Decision number
P/0142/2018
PIP number
EMEA-000527-PIP05-17
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Diabetic retinopathy
Route(s) of administration
Intravitreal use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 6132 41111

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating